Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28890236 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL28411793 | 0.92 | SLC5A2 (0.50) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14321451 | 0.91 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14321244 | 0.87 | SLC5A2 (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16321362 | 0.86 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL30777508 | 0.86 | SLC5A2 (0.66) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189397 | 0.86 | SLC5A2 (0.62) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189394 | 0.85 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19182955 | 0.85 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10228164 | 0.85 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| US-8883743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | ASTRAZENECA AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.